FDA Approves Vyalev for Advanced Parkinson Disease

TUESDAY, Oct. 22, 2024-- The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson disease (PD).Vyalev is the first and only subcutaneous 24-hour continuous infusion of...